{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:00:53Z","timestamp":1791986453812,"version":"4.4.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88887.474436\/2020-00"],"award-info":[{"award-number":["88887.474436\/2020-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88887.506611\/2020-00"],"award-info":[{"award-number":["88887.506611\/2020-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo-FAPESP)","award":["2017\/24832-6"],"award-info":[{"award-number":["2017\/24832-6"]}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["303044\/2020-9"],"award-info":[{"award-number":["303044\/2020-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI116453"],"award-info":[{"award-number":["R01 AI116453"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["REDE-00140-16"],"award-info":[{"award-number":["REDE-00140-16"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bacillus Calmette-Guerin (BCG) is the only FDA approved first line therapy for patients with nonmuscle invasive bladder cancer. The purpose of this study is to better understand the role of innate immune pathways involved in BCG immunotherapy against murine bladder tumor. We first characterized the immunological profile induced by the MB49 mouse urothelial carcinoma cell line. MB49 cells were not able to activate an inflammatory response (TNF-\u03b1, IL-6, CXCL-10 or IFN-\u03b2) after the stimulus with different agonists or BCG infection, unlike macrophages. Although MB49 cells are not able to induce an efficient immune response, BCG treatment could activate other cells in the tumor microenvironment (TME). We evaluated BCG intratumoral treatment in animals deficient for different innate immune molecules (STING<jats:sup>\u2212\/\u2212<\/jats:sup>, cGAS<jats:sup>\u2212\/\u2212<\/jats:sup>, TLR2<jats:sup>\u2212\/\u2212<\/jats:sup>, TLR3<jats:sup>\u2212\/\u2212<\/jats:sup>, TLR4<jats:sup>\u2212\/\u2212<\/jats:sup>, TLR7<jats:sup>\u2212\/\u2212<\/jats:sup>, TLR9<jats:sup>\u2212\/\u2212<\/jats:sup>, TLR3\/7\/9<jats:sup>\u2212\/\u2212<\/jats:sup>, MyD88<jats:sup>\u2212\/\u2212<\/jats:sup>, IL-1R<jats:sup>\u2212\/\u2212<\/jats:sup>, Caspase1\/11<jats:sup>\u2212\/\u2212<\/jats:sup>, Gasdermin-D<jats:sup>\u2212\/\u2212<\/jats:sup> and IFNAR<jats:sup>\u2212\/\u2212<\/jats:sup>) using the MB49 subcutaneous mouse model. Only MyD88<jats:sup>\u2212\/\u2212<\/jats:sup> partially responded to BCG treatment compared to wild type (WT) mice, suggesting a role played by this adaptor molecule. Additionally, BCG intratumoral treatment regulates cellular infiltrate in TME with an increase of inflammatory macrophages, neutrophils and CD8+ T lymphocytes, suggesting an immune response activation that favors tumor remission in WT mice but not in MyD88<jats:sup>\u2212\/\u2212<\/jats:sup>. The experiments using MB49 cells infected with BCG and co-cultured with macrophages also demonstrated that MyD88 is essential for an efficient immune response. Our data suggests that BCG immunotherapy depends partially on the MyD88-related innate immune pathway.<\/jats:p>","DOI":"10.1038\/s41598-021-95157-6","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T10:03:01Z","timestamp":1627898581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model"],"prefix":"10.1038","volume":"11","author":[{"given":"Nina M. G. P.","family":"de Queiroz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio V.","family":"Marinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina V. S. C.","family":"de Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia S.","family":"Fahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio C.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"95157_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","volume":"14","author":"S Farkona","year":"2016","unstructured":"Farkona, S., Diamandis, E. P. & Blasutig, I. M. Cancer immunotherapy: The beginning of the end of cancer?. BMC Med. 14, 73. https:\/\/doi.org\/10.1186\/s12916-016-0623-5 (2016).","journal-title":"BMC Med."},{"key":"95157_CR2","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1097\/01.ju.0000034450.80198.1c","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester, R. J., van der Meijden, A. & Lamm, D. L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J. Urol. 168, 1964\u20131970. https:\/\/doi.org\/10.1097\/01.ju.0000034450.80198.1c (2002).","journal-title":"J. Urol."},{"key":"95157_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur. Urol. 71, 447\u2013461. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041 (2017).","journal-title":"Eur. Urol."},{"key":"95157_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J. Urol. 196, 1021\u20131029. https:\/\/doi.org\/10.1016\/j.juro.2016.06.049 (2016).","journal-title":"J. Urol."},{"key":"95157_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/rru.S63447","volume":"7","author":"O Fuge","year":"2015","unstructured":"Fuge, O., Vasdev, N., Allchorne, P. & Green, J. S. Immunotherapy for bladder cancer. Res. Rep. Urol. 7, 65\u201379. https:\/\/doi.org\/10.2147\/rru.S63447 (2015).","journal-title":"Res. Rep. Urol."},{"key":"95157_CR6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/1097-0142(19930715)72:2<558::aid-cncr2820720237>3.0.co;2-h","volume":"72","author":"H Akaza","year":"1993","unstructured":"Akaza, H. et al. Expression of antitumor response. Role of attachment and viability of bacillus Calmette-Gu\u00e9rin to bladder cancer cells. Cancer 72, 558\u2013563. https:\/\/doi.org\/10.1002\/1097-0142(19930715)72:2%3c558::aid-cncr2820720237%3e3.0.co;2-h (1993).","journal-title":"Cancer"},{"key":"95157_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi, G., Glickman, M. S. & Bochner, B. H. The mechanism of action of BCG therapy for bladder cancer\u2014A current perspective. Nat. Rev. Urol. 11, 153\u2013162. https:\/\/doi.org\/10.1038\/nrurol.2014.15 (2014).","journal-title":"Nat. Rev. Urol."},{"key":"95157_CR8","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.4049\/jimmunol.0904005","volume":"185","author":"DP Simmons","year":"2010","unstructured":"Simmons, D. P. et al. Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9. J. Immunol. (Baltimore, Md.: 1950) 185, 2405\u20132415. https:\/\/doi.org\/10.4049\/jimmunol.0904005 (2010).","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"key":"95157_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.coi.2011.06.002","volume":"23","author":"KK Huynh","year":"2011","unstructured":"Huynh, K. K., Joshi, S. A. & Brown, E. J. A delicate dance: Host response to mycobacteria. Curr. Opin. Immunol. 23, 464\u2013472. https:\/\/doi.org\/10.1016\/j.coi.2011.06.002 (2011).","journal-title":"Curr. Opin. Immunol."},{"key":"95157_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1189\/jlb.0103026","volume":"74","author":"KA Heldwein","year":"2003","unstructured":"Heldwein, K. A. et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J. Leukoc. Biol. 74, 277\u2013286. https:\/\/doi.org\/10.1189\/jlb.0103026 (2003).","journal-title":"J. Leukoc. Biol."},{"key":"95157_CR11","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.micinf.2003.06.001","volume":"5","author":"CM Fremond","year":"2003","unstructured":"Fremond, C. M., Nicolle, D. M., Torres, D. S. & Quesniaux, V. F. Control of Mycobacterium bovis BCG infection with increased inflammation in TLR4-deficient mice. Microbes Infect. 5, 1070\u20131081. https:\/\/doi.org\/10.1016\/j.micinf.2003.06.001 (2003).","journal-title":"Microbes Infect."},{"key":"95157_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1462-5822.2004.00489.x","volume":"7","author":"G Godaly","year":"2005","unstructured":"Godaly, G. & Young, D. B. Mycobacterium bovis bacille Calmette Guerin infection of human neutrophils induces CXCL8 secretion by MyD88-dependent TLR2 and TLR4 activation. Cell. Microbiol. 7, 591\u2013601. https:\/\/doi.org\/10.1111\/j.1462-5822.2004.00489.x (2005).","journal-title":"Cell. Microbiol."},{"key":"95157_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrurol.2013.153","volume":"10","author":"H LaRue","year":"2013","unstructured":"LaRue, H., Ayari, C., Bergeron, A. & Fradet, Y. Toll-like receptors in urothelial cells\u2013targets for cancer immunotherapy. Nat. Rev. Urol. 10, 537\u2013545. https:\/\/doi.org\/10.1038\/nrurol.2013.153 (2013).","journal-title":"Nat. Rev. Urol."},{"key":"95157_CR14","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.juro.2012.11.150","volume":"189","author":"J Falke","year":"2013","unstructured":"Falke, J. et al. Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer. J. Urol. 189, 2077\u20132082. https:\/\/doi.org\/10.1016\/j.juro.2012.11.150 (2013).","journal-title":"J. Urol."},{"key":"95157_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/CJI.0b013e3181587d29","volume":"31","author":"SM Mangsbo","year":"2008","unstructured":"Mangsbo, S. M., Ninalga, C., Essand, M., Loskog, A. & T\u00f6tterman, T. H. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. J. Immunother. (Hagerstown, Md.: 1997) 31, 34\u201342. https:\/\/doi.org\/10.1097\/CJI.0b013e3181587d29 (2008).","journal-title":"J. Immunother. (Hagerstown, Md.: 1997)"},{"key":"95157_CR16","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nature08476","volume":"461","author":"H Ishikawa","year":"2009","unstructured":"Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788\u2013792. https:\/\/doi.org\/10.1038\/nature08476 (2009).","journal-title":"Nature"},{"key":"95157_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm.3813","volume":"21","author":"B Dey","year":"2015","unstructured":"Dey, B. et al. A bacterial cyclic dinucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosis. Nat. Med. 21, 401\u2013406. https:\/\/doi.org\/10.1038\/nm.3813 (2015).","journal-title":"Nat. Med."},{"key":"95157_CR18","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830\u2013842. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.017 (2014).","journal-title":"Immunity"},{"key":"95157_CR19","doi-asserted-by":"publisher","first-page":"5302","DOI":"10.1038\/onc.2014.457","volume":"34","author":"J Ahn","year":"2015","unstructured":"Ahn, J., Konno, H. & Barber, G. N. Diverse roles of STING-dependent signaling on the development of cancer. Oncogene 34, 5302\u20135308. https:\/\/doi.org\/10.1038\/onc.2014.457 (2015).","journal-title":"Oncogene"},{"key":"95157_CR20","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales, L. et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11, 1018\u20131030. https:\/\/doi.org\/10.1016\/j.celrep.2015.04.031 (2015).","journal-title":"Cell Rep."},{"key":"95157_CR21","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ccell.2018.03.027","volume":"33","author":"J Ahn","year":"2018","unstructured":"Ahn, J., Xia, T., Rabasacapote, A., Betancourt, D. & Barber, G. N. Extrinsic phagocyte-dependent STING signaling dictates the immunogenicity of dying cells. Cancer Cell 33, 862\u2013873.e865. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.027 (2018).","journal-title":"Cancer Cell"},{"key":"95157_CR22","doi-asserted-by":"publisher","first-page":"15408","DOI":"10.1073\/pnas.1512832112","volume":"112","author":"O Demaria","year":"2015","unstructured":"Demaria, O. et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc. Natl. Acad. Sci. USA 112, 15408\u201315413. https:\/\/doi.org\/10.1073\/pnas.1512832112 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"95157_CR23","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1038\/ncomms6166","volume":"5","author":"J Ahn","year":"2014","unstructured":"Ahn, J. et al. Inflammation-driven carcinogenesis is mediated through STING. Nat. Commun. 5, 5166. https:\/\/doi.org\/10.1038\/ncomms6166 (2014).","journal-title":"Nat. Commun."},{"key":"95157_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843\u2013852. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.019 (2014).","journal-title":"Immunity"},{"key":"95157_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature23470","volume":"548","author":"SM Harding","year":"2017","unstructured":"Harding, S. M. et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 548, 466\u2013470. https:\/\/doi.org\/10.1038\/nature23470 (2017).","journal-title":"Nature"},{"key":"95157_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2741\/2692","volume":"13","author":"FO Martinez","year":"2008","unstructured":"Martinez, F. O., Sica, A., Mantovani, A. & Locati, M. Macrophage activation and polarization. Front. Biosci. 13, 453\u2013461. https:\/\/doi.org\/10.2741\/2692 (2008).","journal-title":"Front. Biosci."},{"key":"95157_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/s1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549\u2013555. https:\/\/doi.org\/10.1016\/s1471-4906(02)02302-5 (2002).","journal-title":"Trends Immunol."},{"key":"95157_CR28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.urolonc.2013.10.012","volume":"32","author":"L Lima","year":"2014","unstructured":"Lima, L. et al. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure. Urol. Oncol. 32, 449\u2013457. https:\/\/doi.org\/10.1016\/j.urolonc.2013.10.012 (2014).","journal-title":"Urol. Oncol."},{"key":"95157_CR29","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3892\/or.2019.7196","volume":"42","author":"Y Xue","year":"2019","unstructured":"Xue, Y. et al. Tumor-infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer. Oncol. Rep. 42, 581\u2013594. https:\/\/doi.org\/10.3892\/or.2019.7196 (2019).","journal-title":"Oncol. Rep."},{"key":"95157_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1756-9966-32-87","volume":"32","author":"F Suriano","year":"2013","unstructured":"Suriano, F. et al. Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer. J. Exp. Clin. Cancer Res. CR 32, 87. https:\/\/doi.org\/10.1186\/1756-9966-32-87 (2013).","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"95157_CR31","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989\u20132003. https:\/\/doi.org\/10.1084\/jem.20101158 (2011).","journal-title":"J. Exp. Med."},{"key":"95157_CR32","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J. Exp. Med. 208, 2005\u20132016. https:\/\/doi.org\/10.1084\/jem.20101159 (2011).","journal-title":"J. Exp. Med."},{"key":"95157_CR33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","volume":"15","author":"C Pettenati","year":"2018","unstructured":"Pettenati, C. & Ingersoll, M. A. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat. Rev. Urol. 15, 615\u2013625. https:\/\/doi.org\/10.1038\/s41585-018-0055-4 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"95157_CR34","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/mt.2015.216","volume":"24","author":"L Zhang","year":"2016","unstructured":"Zhang, L. et al. Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms. Mol. Ther. J. Am. Soc. Gene Ther. 24, 398\u2013405. https:\/\/doi.org\/10.1038\/mt.2015.216 (2016).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"95157_CR35","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/s0959-8049(99)00057-x","volume":"35","author":"YH Gan","year":"1999","unstructured":"Gan, Y. H., Zhang, Y., Khoo, H. E. & Esuvaranathan, K. Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer. Eur. J. Cancer (Oxford, Engl.: 1990) 35, 1123\u20131129. https:\/\/doi.org\/10.1016\/s0959-8049(99)00057-x (1999).","journal-title":"Eur. J. Cancer (Oxford, Engl.: 1990)"},{"key":"95157_CR36","doi-asserted-by":"publisher","DOI":"10.14440\/bladder.2016.73","author":"S White-Gilbertson","year":"2016","unstructured":"White-Gilbertson, S., Davis, M., Voelkel-Johnson, C. & Kasman, L. M. Sex differences in the MB49 syngeneic, murine model of bladder cancer. Bladder (San Francisco, Calif.) https:\/\/doi.org\/10.14440\/bladder.2016.73 (2016).","journal-title":"Bladder (San Francisco, Calif.)"},{"key":"95157_CR37","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.celrep.2015.12.029","volume":"14","author":"T Xia","year":"2016","unstructured":"Xia, T., Konno, H., Ahn, J. & Barber, G. N. Deregulation of STING signaling in colorectal carcinoma constrains dna damage responses and correlates with tumorigenesis. Cell Rep. 14, 282\u2013297. https:\/\/doi.org\/10.1016\/j.celrep.2015.12.029 (2016).","journal-title":"Cell Rep."},{"key":"95157_CR38","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1158\/0008-5472.Can-16-1404","volume":"76","author":"T Xia","year":"2016","unstructured":"Xia, T., Konno, H. & Barber, G. N. Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis. Can. Res. 76, 6747\u20136759. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-1404 (2016).","journal-title":"Can. Res."},{"key":"95157_CR39","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41388-017-0120-0","volume":"37","author":"H Konno","year":"2018","unstructured":"Konno, H. et al. Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. Oncogene 37, 2037\u20132051. https:\/\/doi.org\/10.1038\/s41388-017-0120-0 (2018).","journal-title":"Oncogene"},{"key":"95157_CR40","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1158\/1541-7786.MCR-18-0504","volume":"17","author":"N de Queiroz","year":"2019","unstructured":"de Queiroz, N., Xia, T., Konno, H. & Barber, G. N. Ovarian cancer cells commonly exhibit defective STING signaling which affects sensitivity to viral oncolysis. Mol. Cancer Res. 17, 974\u2013986. https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-0504 (2019).","journal-title":"Mol. Cancer Res."},{"key":"95157_CR41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.chom.2016.08.002","volume":"20","author":"X Wang","year":"2016","unstructured":"Wang, X. et al. STING requires the adaptor TRIF to trigger innate immune responses to microbial infection. Cell Host Microbe 20, 329\u2013341. https:\/\/doi.org\/10.1016\/j.chom.2016.08.002 (2016).","journal-title":"Cell Host Microbe"},{"key":"95157_CR42","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.cellsig.2014.01.015","volume":"26","author":"W Bai","year":"2014","unstructured":"Bai, W. et al. TLR3 regulates mycobacterial RNA-induced IL-10 production through the PI3K\/AKT signaling pathway. Cell. Signal. 26, 942\u2013950. https:\/\/doi.org\/10.1016\/j.cellsig.2014.01.015 (2014).","journal-title":"Cell. Signal."},{"key":"95157_CR43","first-page":"97","volume":"9","author":"R Pearl","year":"1929","unstructured":"Pearl, R. Cancer and tuberculosis. Am. J. Hygiene. 9, 97\u2013159 (1929).","journal-title":"Am. J. Hygiene."},{"key":"95157_CR44","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/s0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales, A., Eidinger, D. & Bruce, A. W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116, 180\u2013183. https:\/\/doi.org\/10.1016\/s0022-5347(17)58737-6 (1976).","journal-title":"J. Urol."},{"key":"95157_CR45","doi-asserted-by":"publisher","first-page":"2397808","DOI":"10.1155\/2018\/2397808","volume":"2018","author":"K \u0141ukasiewicz","year":"2018","unstructured":"\u0141ukasiewicz, K. & Fol, M. Microorganisms in the treatment of cancer: Advantages and limitations. J. Immunol. Res. 2018, 2397808. https:\/\/doi.org\/10.1155\/2018\/2397808 (2018).","journal-title":"J. Immunol. Res."},{"key":"95157_CR46","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12943-020-01275-6","volume":"19","author":"B Zhang","year":"2020","unstructured":"Zhang, B. & Cheng, P. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy. Mol. Cancer 19, 158. https:\/\/doi.org\/10.1186\/s12943-020-01275-6 (2020).","journal-title":"Mol. Cancer"},{"key":"95157_CR47","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","volume":"33","author":"SJ Russell","year":"2018","unstructured":"Russell, S. J. & Barber, G. N. Oncolytic viruses as antigen-agnostic cancer vaccines. Cancer Cell 33, 599\u2013605. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.011 (2018).","journal-title":"Cancer Cell"},{"key":"95157_CR48","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/jco.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 33, 2780\u20132788. https:\/\/doi.org\/10.1200\/jco.2014.58.3377 (2015).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"95157_CR49","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41585-020-0346-4","volume":"17","author":"JH van Puffelen","year":"2020","unstructured":"van Puffelen, J. H. et al. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nat. Rev. Urol. 17, 513\u2013525. https:\/\/doi.org\/10.1038\/s41585-020-0346-4 (2020).","journal-title":"Nat. Rev. Urol."},{"key":"95157_CR50","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1586\/era.11.163","volume":"11","author":"JHT Stewart","year":"2011","unstructured":"Stewart, J. H. T. & Levine, E. A. Role of bacillus Calmette-Gu\u00e9rin in the treatment of advanced melanoma. Exp. Rev. Anticancer Ther. 11, 1671\u20131676. https:\/\/doi.org\/10.1586\/era.11.163 (2011).","journal-title":"Exp. Rev. Anticancer Ther."},{"key":"95157_CR51","doi-asserted-by":"publisher","first-page":"20222","DOI":"10.18632\/oncotarget.25044","volume":"9","author":"MJ Godoy-Calder\u00f3n","year":"2018","unstructured":"Godoy-Calder\u00f3n, M. J., Salazar, V., Gonz\u00e1lez-Marcano, E. & Convit, A. F. Autologous tumor cells\/bacillus Calmette-Gu\u00e9rin\/formalin-based novel breast cancer vaccine induces an immune antitumor response. Oncotarget 9, 20222\u201320238. https:\/\/doi.org\/10.18632\/oncotarget.25044 (2018).","journal-title":"Oncotarget"},{"key":"95157_CR52","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/s0022-5347(17)42445-1","volume":"139","author":"TL Ratliff","year":"1988","unstructured":"Ratliff, T. L., Kavoussi, L. R. & Catalona, W. J. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J. Urol. 139, 410\u2013414. https:\/\/doi.org\/10.1016\/s0022-5347(17)42445-1 (1988).","journal-title":"J. Urol."},{"key":"95157_CR53","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/bf00184116","volume":"12","author":"B Schneider","year":"1994","unstructured":"Schneider, B. et al. Specific binding of bacillus Calmette-Gu\u00e9rin to urothelial tumor cells in vitro. World J. Urol. 12, 337\u2013344. https:\/\/doi.org\/10.1007\/bf00184116 (1994).","journal-title":"World J. Urol."},{"key":"95157_CR54","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/sj.bjc.6602026","volume":"91","author":"RF Bevers","year":"2004","unstructured":"Bevers, R. F., Kurth, K. H. & Schamhart, D. H. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br. J. Cancer 91, 607\u2013612. https:\/\/doi.org\/10.1038\/sj.bjc.6602026 (2004).","journal-title":"Br. J. Cancer"},{"key":"95157_CR55","first-page":"4286","volume":"52","author":"EC Lattime","year":"1992","unstructured":"Lattime, E. C., Gomella, L. G. & McCue, P. A. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Can. Res. 52, 4286\u20134290 (1992).","journal-title":"Can. Res."},{"key":"95157_CR56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1046\/j.1442-2042.2002.00415.x","volume":"9","author":"N Ikeda","year":"2002","unstructured":"Ikeda, N., Toida, I., Iwasaki, A., Kawai, K. & Akaza, H. Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Gu\u00e9rin (BCG): A role of BCG internalization into tumor cells. Int. J. Urol. Off. J. Japan. Urol. Assoc. 9, 29\u201335. https:\/\/doi.org\/10.1046\/j.1442-2042.2002.00415.x (2002).","journal-title":"Int. J. Urol. Off. J. Japan. Urol. Assoc."},{"key":"95157_CR57","first-page":"181","volume":"9","author":"RF Bevers","year":"1998","unstructured":"Bevers, R. F., de Boer, E. C., Kurth, K. H. & Schamhart, D. H. BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. Eur. Cytokine Netw. 9, 181\u2013186 (1998).","journal-title":"Eur. Cytokine Netw."},{"key":"95157_CR58","doi-asserted-by":"publisher","first-page":"137ra172","DOI":"10.1126\/scitranslmed.3003586","volume":"4","author":"C Biot","year":"2012","unstructured":"Biot, C. et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci. Transl. Med. 4, 137ra172. https:\/\/doi.org\/10.1126\/scitranslmed.3003586 (2012).","journal-title":"Sci. Transl. Med."},{"key":"95157_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12818","volume":"90","author":"S Ohadian Moghadam","year":"2019","unstructured":"Ohadian Moghadam, S. & Nowroozi, M. R. Toll-like receptors: The role in bladder cancer development, progression and immunotherapy. Scand. J. Immunol. 90, e12818. https:\/\/doi.org\/10.1111\/sji.12818 (2019).","journal-title":"Scand. J. Immunol."},{"key":"95157_CR60","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.micinf.2014.09.006","volume":"16","author":"LH Yamashiro","year":"2014","unstructured":"Yamashiro, L. H., Oliveira, S. C. & B\u00e1fica, A. Innate immune sensing of nucleic acids from mycobacteria. Microbes Infect. 16, 991\u2013997. https:\/\/doi.org\/10.1016\/j.micinf.2014.09.006 (2014).","journal-title":"Microbes Infect."},{"key":"95157_CR61","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.tim.2017.05.008","volume":"25","author":"FV Marinho","year":"2017","unstructured":"Marinho, F. V., Benmerzoug, S., Oliveira, S. C., Ryffel, B. & Quesniaux, V. F. J. The emerging roles of STING in bacterial infections. Trends Microbiol. 25, 906\u2013918. https:\/\/doi.org\/10.1016\/j.tim.2017.05.008 (2017).","journal-title":"Trends Microbiol."},{"key":"95157_CR62","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3349\/ymj.1993.34.4.356","volume":"34","author":"CI Kim","year":"1993","unstructured":"Kim, C. I., Shin, J. S., Kim, H. I., Lee, J. M. & Kim, S. J. Production of tumor necrosis factor by intravesical administration of bacillus Calmette Gu\u00e9rin in patients with superficial bladder cancer. Yonsei Med. J. 34, 356\u2013364. https:\/\/doi.org\/10.3349\/ymj.1993.34.4.356 (1993).","journal-title":"Yonsei Med. J."},{"key":"95157_CR63","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","volume":"164","author":"GN Thalmann","year":"2000","unstructured":"Thalmann, G. N. et al. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J. Urol. 164, 2129\u20132133 (2000).","journal-title":"J. Urol."},{"key":"95157_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070940","author":"O Ashiru","year":"2019","unstructured":"Ashiru, O. et al. BCG therapy of bladder cancer stimulates a prolonged release of the chemoattractant CXCL10 (IP10) in patient urine. Cancers https:\/\/doi.org\/10.3390\/cancers11070940 (2019).","journal-title":"Cancers"},{"key":"95157_CR65","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2326-6066.Cir-16-0284","volume":"5","author":"JB Foote","year":"2017","unstructured":"Foote, J. B. et al. A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice. Cancer Immunol. Res. 5, 468\u2013479. https:\/\/doi.org\/10.1158\/2326-6066.Cir-16-0284 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"95157_CR66","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618. https:\/\/doi.org\/10.1038\/ncomms15618 (2017).","journal-title":"Nat. Commun."},{"key":"95157_CR67","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.25.061531","author":"AK Singh","year":"2020","unstructured":"Singh, A. K. et al. Recombinant BCG overexpressing a STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer. J. bioRxiv https:\/\/doi.org\/10.1101\/2020.04.25.061531 (2020).","journal-title":"J. bioRxiv"},{"key":"95157_CR68","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00262-015-1789-y","volume":"65","author":"C Ayari","year":"2016","unstructured":"Ayari, C. et al. Poly(I:C) potentiates Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer. Cancer Immunol. Immunother. CII 65, 223\u2013234. https:\/\/doi.org\/10.1007\/s00262-015-1789-y (2016).","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"95157_CR69","doi-asserted-by":"publisher","first-page":"1771143","DOI":"10.1080\/2162402x.2020.1771143","volume":"9","author":"J Le Naour","year":"2020","unstructured":"Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G. & Vacchelli, E. Trial watch: TLR3 agonists in cancer therapy. Oncoimmunology 9, 1771143. https:\/\/doi.org\/10.1080\/2162402x.2020.1771143 (2020).","journal-title":"Oncoimmunology"},{"key":"95157_CR70","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/s0968-0004(02)02145-x","volume":"27","author":"S Janssens","year":"2002","unstructured":"Janssens, S. & Beyaert, R. A universal role for MyD88 in TLR\/IL-1R-mediated signaling. Trends Biochem. Sci. 27, 474\u2013482. https:\/\/doi.org\/10.1016\/s0968-0004(02)02145-x (2002).","journal-title":"Trends Biochem. Sci."},{"key":"95157_CR71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nri1997","volume":"7","author":"S Mariathasan","year":"2007","unstructured":"Mariathasan, S. & Monack, D. M. Inflammasome adaptors and sensors: Intracellular regulators of infection and inflammation. Nat. Rev. Immunol. 7, 31\u201340. https:\/\/doi.org\/10.1038\/nri1997 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"95157_CR72","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s0022-5347(17)43909-7","volume":"137","author":"TL Ratliff","year":"1987","unstructured":"Ratliff, T. L., Gillen, D. & Catalona, W. J. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J. Urol. 137, 155\u2013158. https:\/\/doi.org\/10.1016\/s0022-5347(17)43909-7 (1987).","journal-title":"J. Urol."},{"key":"95157_CR73","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/s0022-5347(17)35678-1","volume":"150","author":"TL Ratliff","year":"1993","unstructured":"Ratliff, T. L., Ritchey, J. K., Yuan, J. J., Andriole, G. L. & Catalona, W. J. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol. 150, 1018\u20131023. https:\/\/doi.org\/10.1016\/s0022-5347(17)35678-1 (1993).","journal-title":"J. Urol."},{"key":"95157_CR74","doi-asserted-by":"publisher","first-page":"110393","DOI":"10.1016\/j.biopha.2020.110393","volume":"129","author":"J Han","year":"2020","unstructured":"Han, J., Gu, X., Li, Y. & Wu, Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed. Pharmacother. Biomedecine Pharmacotherapie 129, 110393. https:\/\/doi.org\/10.1016\/j.biopha.2020.110393 (2020).","journal-title":"Biomed. Pharmacother. Biomedecine Pharmacotherapie"},{"key":"95157_CR75","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cellimm.2018.01.018","volume":"330","author":"L Lacerda Mariano","year":"2018","unstructured":"Lacerda Mariano, L. & Ingersoll, M. A. Bladder resident macrophages: Mucosal sentinels. Cell. Immunol. 330, 136\u2013141. https:\/\/doi.org\/10.1016\/j.cellimm.2018.01.018 (2018).","journal-title":"Cell. Immunol."},{"key":"95157_CR76","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/bf01741551","volume":"34","author":"EC De Boer","year":"1992","unstructured":"De Boer, E. C. et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin in superficial bladder cancer. Cancer Immunol. Immunother. CII 34, 306\u2013312. https:\/\/doi.org\/10.1007\/bf01741551 (1992).","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"95157_CR77","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2249.1995.tb05560.x","volume":"99","author":"AM Jackson","year":"1995","unstructured":"Jackson, A. M. et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy. Clin. Exp. Immunol. 99, 369\u2013375. https:\/\/doi.org\/10.1111\/j.1365-2249.1995.tb05560.x (1995).","journal-title":"Clin. Exp. Immunol."},{"key":"95157_CR78","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1442-2042.2007.01696.x","volume":"14","author":"Y Shintani","year":"2007","unstructured":"Shintani, Y. et al. Intravesical instillation therapy with bacillus Calmette-Gu\u00e9rin for superficial bladder cancer: Study of the mechanism of bacillus Calmette-Gu\u00e9rin immunotherapy. Int. J. Urol. Off. J. Japan. Urol. Assoc. 14, 140\u2013146. https:\/\/doi.org\/10.1111\/j.1442-2042.2007.01696.x (2007).","journal-title":"Int. J. Urol. Off. J. Japan. Urol. Assoc."},{"key":"95157_CR79","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1172\/jci6224","volume":"103","author":"J Wang","year":"1999","unstructured":"Wang, J., Wakeham, J., Harkness, R. & Xing, Z. Macrophages are a significant source of type 1 cytokines during mycobacterial infection. J. Clin. Investig. 103, 1023\u20131029. https:\/\/doi.org\/10.1172\/jci6224 (1999).","journal-title":"J. Clin. Investig."},{"key":"95157_CR80","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/bjc.1998.545","volume":"78","author":"OT Jansson","year":"1998","unstructured":"Jansson, O. T. et al. The role of nitric oxide in bacillus Calmette-Gu\u00e9rin mediated anti-tumour effects in human bladder cancer. Br. J. Cancer 78, 588\u2013592. https:\/\/doi.org\/10.1038\/bjc.1998.545 (1998).","journal-title":"Br. J. Cancer"},{"key":"95157_CR81","doi-asserted-by":"publisher","first-page":"39916","DOI":"10.18632\/oncotarget.9537","volume":"7","author":"R Pichler","year":"2016","unstructured":"Pichler, R. et al. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Gu\u00e9rin therapy in bladder cancer. Oncotarget 7, 39916\u201339930. https:\/\/doi.org\/10.18632\/oncotarget.9537 (2016).","journal-title":"Oncotarget"},{"issue":"45","key":"95157_CR82","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.urolonc.2013.06.005","volume":"32","author":"G Shah","year":"2014","unstructured":"Shah, G. et al. iNOS expression and NO production contribute to the direct effects of BCG on urothelial carcinoma cell biology. Urol. Oncol. 32(45), e41-49. https:\/\/doi.org\/10.1016\/j.urolonc.2013.06.005 (2014).","journal-title":"Urol. Oncol."},{"key":"95157_CR83","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.juro.2014.05.115","volume":"192","author":"G Shah","year":"2014","unstructured":"Shah, G. et al. H2O2 generation by bacillus Calmette-Gu\u00e9rin induces the cellular oxidative stress response required for bacillus Calmette-Gu\u00e9rin direct effects on urothelial carcinoma biology. J. Urol. 192, 1238\u20131248. https:\/\/doi.org\/10.1016\/j.juro.2014.05.115 (2014).","journal-title":"J. Urol."},{"key":"95157_CR84","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.1365-2249.2002.01734.x","volume":"127","author":"J Riemensberger","year":"2002","unstructured":"Riemensberger, J., B\u00f6hle, A. & Brandau, S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin. Exp. Immunol. 127, 20\u201326. https:\/\/doi.org\/10.1046\/j.1365-2249.2002.01734.x (2002).","journal-title":"Clin. Exp. Immunol."},{"key":"95157_CR85","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2249.2010.04105.x","volume":"160","author":"Y Luo","year":"2010","unstructured":"Luo, Y., Han, R., Evanoff, D. P. & Chen, X. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG)-induced macrophage cytotoxicity against bladder cancer cells. Clin. Exp. Immunol. 160, 359\u2013368. https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04105.x (2010).","journal-title":"Clin. Exp. Immunol."},{"key":"95157_CR86","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1756-9966-27-78","volume":"27","author":"DC Chade","year":"2008","unstructured":"Chade, D. C. et al. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J. Exp. Clin. Cancer Res. CR 27, 78. https:\/\/doi.org\/10.1186\/1756-9966-27-78 (2008).","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"95157_CR87","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1126\/science.7535475","volume":"267","author":"K Kuida","year":"1995","unstructured":"Kuida, K. et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267, 2000\u20132003. https:\/\/doi.org\/10.1126\/science.7535475 (1995).","journal-title":"Science"},{"key":"95157_CR88","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nature15541","volume":"526","author":"N Kayagaki","year":"2015","unstructured":"Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666\u2013671. https:\/\/doi.org\/10.1038\/nature15541 (2015).","journal-title":"Nature"},{"key":"95157_CR89","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature07317","volume":"455","author":"H Ishikawa","year":"2008","unstructured":"Ishikawa, H. & Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674\u2013678. https:\/\/doi.org\/10.1038\/nature07317 (2008).","journal-title":"Nature"},{"key":"95157_CR90","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/jlb.4ma0620-526rr","volume":"108","author":"FV Marinho","year":"2020","unstructured":"Marinho, F. V. et al. Guanylate binding proteins contained in the murine chromosome 3 are important to control mycobacterial infection. J. Leukoc. Biol. 108, 1279\u20131291. https:\/\/doi.org\/10.1002\/jlb.4ma0620-526rr (2020).","journal-title":"J. Leukoc. Biol."},{"key":"95157_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007519","volume":"14","author":"DM Cerqueira","year":"2018","unstructured":"Cerqueira, D. M. et al. Guanylate-binding protein 5 licenses caspase-11 for Gasdermin-D mediated host resistance to Brucella abortus infection. PLoS Pathog. 14, e1007519. https:\/\/doi.org\/10.1371\/journal.ppat.1007519 (2018).","journal-title":"PLoS Pathog."},{"key":"95157_CR92","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.4049\/jimmunol.1801233","volume":"202","author":"ES Guimaraes","year":"2019","unstructured":"Guimaraes, E. S. et al. Brucella abortus cyclic dinucleotides trigger STING-dependent unfolded protein response that favors bacterial replication. J. Immunol. (Baltimore, Md.: 1950) 202, 2671\u20132681. https:\/\/doi.org\/10.4049\/jimmunol.1801233 (2019).","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95157-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95157-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95157-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:02:50Z","timestamp":1670068970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95157-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["95157"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-95157-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"15 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15648"}}